Abstract
During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Current HIV Research
Title:β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin
Volume: 10 Issue: 4
Author(s): Fabien P. Blanchet, J. P. Mitchell and Vincent Piguet
Affiliation:
Keywords: BST-2/tetherin, CD4, Human Immunodeficiency Virus-1 (HIV-1), lysosome, proteasome, SCFbTrCP E3 ubiquitin ligase, Ubiquitination, Viral Protein U (Vpu), degradation, proteolysis
Abstract: During evolution, pathogens have evolved strategies to counteract key cellular restriction mechanisms in order to efficiently invade target cells and fulfill essential steps of their replication cycle. Human Immunodeficiency Virus-1 and some Simian counterparts express a small multifunctional protein, Vpu, which influences viral replication. By acting as a multifunctional adapter, Vpu enhances viral particle release and infectivity. Therefore Vpu, an accessory protein, contributes to pathogenesis while avoiding superinfection. These effects rely mainly on the ability of Vpu to target the host proteins CD4 and BST-2/tetherin. Indeed, Vpu downregulates the cell surface expression of these receptors and subsequently induces their proteolysis via a mechanism involving a β -TrCP-containing E3 ubiquitin ligase complex. In this review, we will detail recent research aimed at elucidating the mechanism of Vpu-mediated CD4 and BST-2/tetherin downregulation and degradation as well as their subsequent consequences on viral pathogenesis.
Export Options
About this article
Cite this article as:
P. Blanchet Fabien, P. Mitchell J. and Piguet Vincent, β -TrCP Dependency of HIV-1 Vpu-Induced Downregulation of CD4 and BST-2/Tetherin, Current HIV Research 2012; 10(4) . https://dx.doi.org/10.2174/157016212800792441
DOI https://dx.doi.org/10.2174/157016212800792441 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Clinical Use of Intracoronary Gene Transfer of Fibroblast Growth Factor for Coronary Artery Disease
Current Gene Therapy Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Unified Multi-target Approach for the Rational in silico Design of Anti-bladder Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Current Cancer Drug Targets A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Reviews on Recent Clinical Trials Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets
Current Cancer Drug Targets Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) PET Imaging with [<sup>68</sup>Ga]NOTA-RGD for Prostate Cancer: A Comparative Study with [<sup>18</sup>F]Fluorodeoxyglucose and [<sup>18</sup>F]Fluoroethylcholine
Current Cancer Drug Targets Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine